Alteogen Inc.
196170
주식 순위
#1894
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
주가
$159.04
시가총액
$11.07B
변동 (1일)
-2.95%
변동 (1년)
-48.94%
국가
KR
거래 Alteogen Inc. (196170)
카테고리
Healthcare
Alteogen Inc. (196170)의 EPS
June 2026 기준 EPS TTM: $2.18
Alteogen Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $2.18입니다. 2023년 말에는 회사의 EPS가 $-0.05였으며, 이는 2022년의 EPS $-0.13와 감소입니다.
Alteogen Inc.의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $2.18 | 172.34% |
| 2024 | $0.80 | -1,681.75% |
| 2023 | $-0.05 | -59.97% |
| 2022 | $-0.13 | 44.88% |
| 2021 | $-0.09 | -54.97% |
| 2020 | $-0.19 | 1,419.69% |
| 2019 | $-0.01 | -90.64% |
| 2018 | $-0.14 | -12.79% |
| 2017 | $-0.16 | 126.82% |
| 2016 | $-0.07 | -382.30% |
| 2015 | $0.02 | -10.00% |
| 2014 | $0.03 | -66.17% |
| 2013 | $0.08 | -1.60% |
| 2012 | $0.08 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | 694.97% |
US
|
|
| $-7.98 | -466.27% |
US
|
|
| $-5.29 | -342.81% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,173.24% |
NL
|
